Medicare Enrolled
Dr. Mona Lisa Alattar, M.D.
Hematology & Oncology · Houston, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Alattar from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Alattar?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Alattar
Dr. Mona Lisa Alattar is a hematology & oncology specialist in Houston, TX, with 13 years of NPI registration. Based on federal Medicare data, Dr. Alattar performed 6,435 Medicare services across 673 unique beneficiaries.
Between the years covered by Open Payments, Dr. Alattar received a total of $18,176 from 86 pharmaceutical and/or device companies across 737 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Alattar is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 13 years in practice
▲ Top 38% volume in TX
$18,176 industry payments
Medicare Practice Summary
Medicare Utilization ↗6,435
Medicare services
Top 38% in TX for hematology & oncology
673
Unique beneficiaries
$19
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~495 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Contrast dye for imaging (iodine-based) | 2,200 | $0 | $0 |
| Dexamethasone injection (steroid) | 1,222 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 950 | $1 | $4 |
| Complete blood count (CBC) with differential | 550 | $8 | $24 |
| Office visit, established patient (30-39 min) | 295 | $94 | $394 |
| Administration of chemotherapy into vein, 1 hour or less | 172 | $104 | $416 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 168 | $23 | $92 |
| Injection of additional new drug or substance into vein | 140 | $12 | $55 |
| Blood draw (venipuncture) | 134 | $8 | $10 |
| Drug injection, under skin or into muscle | 112 | $11 | $52 |
| Administration of additional new drug or substance into vein, 1 hour or less | 98 | $52 | $204 |
| Administration of chemotherapy into vein, each additional hour | 88 | $23 | $90 |
| Office visit, established patient (20-29 min) | 67 | $59 | $275 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 62 | $48 | $203 |
| New patient office visit (45-59 min) | 47 | $120 | $515 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 33 | $1,179 | $5,631 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 33 | $101 | $453 |
| Blood test, basic group of blood chemicals (calcium, ionized) | 27 | $13 | $42 |
| Office visit, established patient, complex (40-54 min) | 22 | $135 | $552 |
| Blood creatinine level | 15 | $5 | $16 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
3.6% high complexity
76.4% medium
20.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$18,176
Total received (2018-2024)
Avg $2,597/year across 7 years
Top 22% in TX for hematology & oncology
86
Companies
737
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$14,051 (77.3%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$3,532 (19.4%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$593 (3.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,521
2023
$2,239
2022
$6,120
2021
$2,054
2020
$1,465
2019
$1,911
2018
$1,865
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$3,969
Novartis Pharmaceuticals Corporation
$1,290
Celgene Corporation
$933
Amgen Inc.
$927
E.R. Squibb & Sons, L.L.C.
$914
Janssen Biotech, Inc.
$886
PFIZER INC.
$722
GENZYME CORPORATION
$656
Bayer HealthCare Pharmaceuticals Inc.
$629
Merck Sharp & Dohme LLC
$456
Incyte Corporation
$451
Genentech USA, Inc.
$403
Seagen Inc.
$371
Gilead Sciences, Inc.
$304
Eisai Inc.
$299
SpringWorks Therapeutics, Inc.
$280
GlaxoSmithKline, LLC.
$279
Merck Sharp & Dohme Corporation
$279
MorphoSys, US Inc.
$267
Janssen Pharmaceuticals, Inc
$262
Lilly USA, LLC
$251
Taiho Oncology, Inc.
$200
Takeda Pharmaceuticals U.S.A., Inc.
$198
Pharmacyclics LLC, An AbbVie Company
$156
Pharmacyclics LLC, an AbbVie Company
$141
PharmaEssentia USA Corporation
$140
Foundation Medicine, Inc.
$127
TerSera Therapeutics LLC
$115
Teva Pharmaceuticals USA, Inc.
$107
ARRAY BIOPHARMA INC
$104
Astellas Pharma US Inc
$100
Exelixis Inc.
$90
Daiichi Sankyo Inc.
$89
TESARO, Inc.
$86
Regeneron Healthcare Solutions, Inc.
$82
Sirtex Medical Inc
$81
Puma Biotechnology, Inc.
$79
Rigel Pharmaceuticals, Inc.
$77
Kyowa Kirin, Inc.
$74
Clovis Oncology, Inc.
$61
Stemline Therapeutics Inc.
$57
Lexicon Pharmaceuticals, Inc.
$53
Bayer Healthcare Pharmaceuticals Inc.
$51
Deciphera Pharmaceuticals Inc.
$49
Tempus AI, Inc
$44
AbbVie, Inc.
$41
Servier Pharmaceuticals LLC
$39
Mylan Institutional Inc.
$39
Blueprint Medicines Corporation
$38
Pharmacosmos Therapeutics Inc.
$35
TAIHO ONCOLOGY, INC.
$34
Amneal Pharmaceuticals LLC
$32
Secura Bio, Inc.
$30
Agios Pharmaceuticals, Inc.
$29
Tactile Systems Technology Inc
$27
Emmaus Medical, Inc.
$27
EMD Serono, Inc.
$26
Myovant Sciences Inc.
$26
Kite Pharma, Inc.
$25
Boston Scientific Corporation
$25
BeiGene USA, Inc.
$25
G1 Therapeutics, Inc.
$24
Alexion Pharmaceuticals, Inc.
$24
Ipsen Biopharmaceuticals, Inc
$24
AbbVie Inc.
$24
Electronic Waveform Lab, Inc.
$23
Boehringer Ingelheim Pharmaceuticals, Inc.
$23
JAZZ PHARMACEUTICALS INC.
$22
AVEO Pharmaceuticals, Inc.
$22
Acceleron Pharma, Inc.
$22
Apellis Pharmaceuticals, Inc.
$22
PUMA BIOTECHNOLOGY, INC.
$22
EUSA Pharma (US) LLC
$21
Sumitomo Pharma America, Inc.
$20
Epizyme, Inc.,
$20
Biocompatibles, Inc.
$20
Sysmex Inostics Inc
$18
Alnylam Pharmaceuticals Inc.
$18
Genmab U.S., Inc.
$17
ABBVIE INC.
$17
MACROGENICS, INC.
$17
Otsuka America Pharmaceutical, Inc.
$16
Karyopharm Therapeutics Inc.
$16
AMAG Pharmaceuticals, Inc.
$14
Seattle Genetics, Inc.
$12
Fennec Pharmaceuticals, Inc.
$11
Top 3 companies account for 34.1% of total payments
Associated products mentioned in payments ›
ABECMA · ADAKVEO · ADCETRIS · AFINITOR · ALIMTA · ALUNBRIG · AVASTIN · AYVAKIT · Abraxane · Alecensa · Aliqopa · Aranesp · BENDEKA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Blincyto · CABLIVI · CABOMETYX · CALQUENCE · CARVYKTI · CHANTIX · COSELA · CYRAMZA · Cabometyx · Columvi · DARZALEX · ELZONRIS · ENHERTU · ENJAYMO · EPKINLY · ERBITUX · ERLEADA · Empaveli · Endari · Enhertu · Erleada · FARYDAK · FERAHEME · FOTIVDA · FOUNDATIONONE · Fabhalta · Flexitouch Plus · GAVRETO · GAZYVA · GILOTRIF · GIVLAARI · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INREBIC · Imbruvica · JADENU · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · MARGENZA · MEKINIST · MONJUVI · MONOFERRIC · MYLOTARG · NERLYNX · NINLARO · Nerlynx · Neulasta · Nexavar · Nplate · Nubeqa · OGSIVEO · OJJAARA · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Ogivri · Onivyde · Orserdu · PADCEV · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · Pedmark · Perjeta · Polivy · Pomalyst · Prolia · QINLOCK · REBLOZYL · RYBREVANT · RYDAPT · Reblozyl · Revlimid · Rezlidhia · Rubraca · SARCLISA · SCEMBLIX · SHINGRIX · SIR-Spheres Microspheres · SPRYCEL · SUTENT · Stivarga · Sylvant · TABRECTA · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · THERASPHERE-BIO · TIBSOVO · TUKYSA · Tavalisse · Tecentriq · TheraSphere Y90 Glass Microspheres 10 GBq · Tivdak · Trodelvy · Truxima · ULTOMIRIS · VENCLEXTA · VERZENIO · VOTRIENT · Vectibix · Venclexta · XALKORI · XARELTO · XGEVA · XOSPATA · XPOVIO · XTANDI · XYNTHA · Xermelo · Xofigo · Xospata · ZEJULA · ZOLADEX
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (77%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $282 per 100 Medicare services performed
Geographic Context
Hematology & oncology specialists within 10 mi
198
Per 100K population
4.2
County median income
$73,104
Nearest hospital
MEMORIAL HERMANN MEMORIAL CITY HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Alattar is a mixed practice specialist, with moderate Medicare volume, with low-engagement industry engagement.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Alattar experienced with contrast dye for imaging (iodine-based)?
Based on Medicare claims data, Dr. Alattar performed 2,200 contrast dye for imaging (iodine-based) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Alattar receive payments from pharmaceutical companies?
Yes. Dr. Alattar received a total of $18,176 from 86 companies across 737 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Alattar's costs compare to other hematology & oncology specialists in Houston?
Dr. Alattar's average Medicare payment per service is $19. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Alattar) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Houston
Browse hematology & oncology specialists in Houston ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in TX
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in TX
Which TX hematology & oncology specialists receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology